86215-36-3

Usage

Uses

Used in Medicinal Chemistry:
1-(3,4-DICHLORO-PHENYL)-3-AZA-BICYCLO[3.1.0]HEXANE HCL is used as a compound with potential pharmacological properties for the development of new drugs and therapies.
Used in Drug Development:
In the pharmaceutical industry, 1-(3,4-DICHLORO-PHENYL)-3-AZA-BICYCLO[3.1.0]HEXANE HCL is used as a candidate molecule for targeting specific receptors or enzymes in the body, potentially leading to the discovery of novel treatments for various diseases and conditions.

InChI:InChI=1/C11H11Cl2N.ClH/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11;/h1-3,8,14H,4-6H2;1H

Upstream product

• 6725-44-6 methyl 2-(3,4-dichlorophenyl)acetate 
• 344245-65-4 1-(3,4-dichlorophenyl)-1,2-cyclopropanedicarboxylic acid 
• 163339-71-7 α-bromo-3,4-dichlorophenylacetic acid methyl ester 
• 877397-17-6 1-(3,4-dichlorophenyl)-1,2-cyclopropane-dicarboxylic acid dimethyl ester 
• 3218-49-3 3,4-dichloro-benzeneacetonitrile 
• 66504-44-7 (±)-1-(3,4 dichlorophenyl)-3-azabicyclo[3.1.0]-hexane-2,4-dione 
• 67644-29-5 1-(4-chlorophenyl)-3-azabicyclo[3.1.0]hexane 

Downstream Products

• 410074-74-7 hydrochloride salt of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane 
• 410074-74-7 Amitifadine hydrochloride 
• 410074-74-7 DOV 21,947 

Relevant academic research and scientific papers

USE OF AMITIFADINE, (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN METHODS AND COMPOSITIONS WITH ENHANCED EFFICACY AND REDUCED METABOLIC SIDE EFFECTS AND TOXICITY FOR TREATMENT OF DEPRESSION AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIO

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azab

PREPARATION AND USE OF (+)-1-(3,4-DICHLOROPHENYL)-3-AZABICYCLO[3.1.0]HEXANE IN THE TREATMENT OF CONDITIONS AFFECTED BY MONOAMINE NEUROTRANSMITTERS

The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable active salts, polymorphs, glycosylated derivatives, metabolites, solvates, hydrates, and/or prodrugs of (+)-1-(3,4-dichlorophenyl)-3-azab

Novel polymorphs of azabicyclohexane

The invention provides polymorphic crystalline forms of acid addition salts of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane designated as polymorph form A, polymorph form B and polymorph form C, where polymorph form A is more thermodynamically stable than the other forms, methods for preparing and using such polymorph forms and pharmaceutical compositions containing such polymorph forms.

(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor

The present invention relates to (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (?)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.

Method of treating depression using azabicyclohexanes

The present invention concerns certain novel substituted 3-azabicyclo[3.1.0]hexanes and a method of treating depression and stress in a warm-blooded animal, comprising the administration of substituted 3-azabicyclo[3.1.0]hexanes.

Azabicyclohexanes

Substituted 3-azabicyclo[3.1.0]hexanes, acid addition salts, method of use and method of preparation are described. The compounds have anxiolytic and analgesic activity.